Statement on combined hormonal contraceptives containing third-or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism

European Journal of Contraception and Reproductive Health Care

Volumn 18, Issue 3, 2013, Pages 143-147

  Bitzer, Johannes ^a   Amy, Jean Jacques ^b   Beerthuizen, Rob ^c   Birkhäuser, Martin ^d   Bombas, Teresa ^e   Creinin, Mitchell ^f   Darney, Philip D ^g   Vicente, Lisa Ferreira ^h   Gemzell Danielsson, Kristina ⁱ   Imthurn, Bruno ^j   Jensen, Jeffrey T ^k   Kaunitz, Andrew M ^l   Kubba, Ali ^m   Lech, Medard M ⁿ   Mansour, Diana ^o   Merki, Gabriele ^p   Rabe, Thomas ^q   Sedlecki, Katarina ^r   Serfaty, David ^s   Seydoux, Jacques ^t   Shulman, Lee P ^u   Sitruk Ware, Regine ^v   Skouby, Sven O ^w   Szarewski, Anne ^x   Trussell, James ^y   Westhoff, Carolyn ^z   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Jean Jacques Amy   (Belgium)

^c Rob Beerthuizen ^*  (Netherlands)

^d Martin Birkhäuser   (Switzerland)

^e Teresa Bombas   (Portugal)

^f Mitchell Creinin   (United States)

^g Philip D Darney   (United States)

^h Lisa Ferreira Vicente   (Portugal)

ⁱ Kristina Gemzell Danielsson   (Sweden)

^j Bruno Imthurn   (Switzerland)

^k Jeffrey T Jensen   (United States)

^l Andrew M Kaunitz   (United States)

^m Ali Kubba   (United Kingdom)

ⁿ Medard M Lech   (Poland)

^o Diana Mansour   (United Kingdom)

^p Gabriele Merki   (Switzerland)

^q Thomas Rabe   (Germany)

^r Katarina Sedlecki   (Serbia)

^s David Serfaty   (France)

^t Jacques Seydoux   (Switzerland)

^u Lee P Shulmann   (United States)

^v Regine Sitruk Ware   (United States)

^w Sven O Skouby   (Denmark)

^x Anne Szarewski   (United Kingdom)

^y James Trussell   (United States)

^z Carolyn Westhoff   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; GESTAGEN; GESTODENE; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; GEOGRAPHIC DISTRIBUTION; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; CYPROTERONE ACETATE; EUROPE; FEMALE; HUMANS; PROGESTINS; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

EID: 84877829407     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2013.792637     Document Type: Article

References (27)

1. Lidegaard Ø , Løkkegaard E , Svendsen AL, et a l . Hormonal contraception and risk of venous thromboembolism: national follow-up study . BMJ 2009 ; 339 : b2890 .
2. van Hylckama Vlieg A , Helmerhorst F M, Vandenbroucke JP , et al . The venous thrombotic risk of oral contraceptives, effects of estrogen dose and progestagen type: results of the MEGA case-control study . BMJ 2009 ; 339 : b2921 .
3. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: casecontrol study using United States claims data . BMJ 2011 ; 340 : d2151 .
4. Parkin L, Sharples K , Hernandez RK, et al . Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database . BMJ 2011 ; 340 : d2139 .
5. Lidegaard Ø , Nielsen L H, Skovlund C W, et a l . R isk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 . BMJ 2011 ; 343 : d6423 .
6. Theinemann L AJ, Dinger J C. Range of published estimates of venous thromboembolism incidence in young women . Contraception 2007 ; 75 : 328-336 .
7. Martí nez F , Ramí rez I , Pé r ez-Campos E , et a l. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis . Eur J Contracept Reprod Health Care 2012 ; 17 : 7-29 .
8. Dinger JC, Heinemann LAJ, Kuhl-Habich D . The safety of a drospirenone-containing oral contraceptive: fi nal results from the European Active Surveillance Study on Oral Contraceptives based on 142,475 women-years of observation . Contraception 2007 ; 75 : 344-354 . (Pubitemid 46551071)
9. Seeger J D , Loughlin J , E ng P M, et a l. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives . Obstet Gynecol 2007 ; 110 : 587-593 . (Pubitemid 47359582)
10. Skjeldestad FE. Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives . Contraception 1997 ; 55 : 11-14 . (Pubitemid 27036584)
11. Goodyear-Smith A, Arroll B . Termination of pregnancy following panic-stopping of oral contraceptives . Contraception 2002 ; 66 : 163-167 . (Pubitemid 35217866)
12. Van Vliet HAA, Winkel TA, Noort I , et al . Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate . J Thromb Haemost 2004 ; 2 : 2060-2062 . (Pubitemid 40192767)
13. Lidegaard Ø , Nielsen L H, Skovlund C W, e t a l. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 . BMJ 2012 ; 344 : e2990 .
14. Lidegaard Ø , Milsom I , Geirssons RT, et al . Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand 2012 ; 91 : 769-778 .
15. Dinger J , P ineda A A . R isk of VTE in users of an etonogestrel- containing vaginal ring and combined oral contraceptives . Paper presented at the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) , San Diego, CA, USA , 7 May 2012 .
16. Spitzer W O . The aftermath of a pill scare: regression to reassurance . Hum Reprod Update 1999 ; 5 : 736-745 . (Pubitemid 30034895)
17. Lewis M A , MacRae K D , Kuhl-Habichl D , et a l . The differential risk of oral contraceptives: the impact of full exposure history . Hum Reprod 1999 ; 14 : 1493-1499 . (Pubitemid 29265441)
18. Dinger J . Oral contraceptives and venous thromboembolism: old questions revisited . J Fam Plann Reprod Health Care 2009 ; 35 : 211-213 .
19. Shapiro S , Dinger J . Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies . J Fam Plann Reprod Health Care 2010 ; 36 : 33-38 .
20. Theinemann K , Heinemann L A. Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel . J Fam Plann Reprod Health Care 2011 ; 37 : 132-135 .
21. Reid R L, Westhoff C , Mansour D , e t a l. Oral contraceptives and venous thromboembolism-Consensus opinion from an international workshop held in Berlin, Germany in December 2009 . J Fam Plann Reprod Health Care 2010; 36 : 117-122 .
22. Jensen JT, Trussell J . Communicating risk: does scientifi c debate compromise safety . Contraception 2012 ; 86 : 327-329 .
23. World Health Organization . M edical Eligibility for Contraceptive Use (4th edn) . 2010 . http://www.who.int/reproducti vehealth/publications/family- planning/9789241563888/en/index.html [accessed 6 March 2013].
24. Dinger J , Shapiro S . Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets . J Fam Plann Reprod Health Care 2012 ; 38 : 2-6 .
25. Hannaford PC, Iversen L. Mortality among oral contraceptive users: an evolving story . Eur J Contracept Reprod Health Care 2013 ; 18 : 1-4 .
26. Hannaford P C, Iversen L , MacFarlane T V, e t al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners ' Oral Contraception Study . BMJ 2010 ; 340 : c927 .
27. Vessey M, Yeates D , Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use . Contraception 2010 ; 82 : 221-229